Report Highlights

U.S. Corneal Cross-Linking Devices: Market Overview

The U.S. corneal cross-linking devices market is structured around a tightly regulated procedural framework established by the FDA's 2016 approval of Avedro's KXL system — now commercialised through Glaukos Corporation following its 2021 acquisition. This regulatory event defined the standard of care as accelerated epithelium-off cross-linking using riboflavin ophthalmic solution (Photrexa Viscous) and UV-A delivery at 365 nm. The market remains heavily provider-driven, with academic medical centres and high-volume refractive surgery practices accounting for the majority of procedure volume, while private equity-backed ophthalmology chains are rapidly expanding access points across suburban markets.

Government and regulatory bodies, specifically the FDA's Center for Devices and Radiological Health (CDRH) and the Centers for Medicare and Medicaid Services (CMS), have been the dominant structural forces in this market. CMS assigned CPT code 0402T for corneal cross-linking in 2016, and its subsequent reclassification to Category I CPT code 92145 in 2020 was the single most consequential demand stimulus, enabling broader commercial insurance coverage. Private sector innovation has concentrated on next-generation UV-A delivery platforms and epi-on riboflavin formulations, but all commercial activity remains anchored to the FDA-cleared procedural pathway and payer acceptance of that specific code.

Policy-Driven Growth in Corneal Cross-Linking

The reclassification of corneal cross-linking to CPT Category I code 92145, effective January 2020 through the American Medical Association's CPT Editorial Panel process, is the primary policy mechanism driving sustained demand growth. Category I status signals clinical efficacy recognition and triggers mandatory coverage review by commercial payers. By 2023, over 85% of major commercial insurers had issued positive coverage determinations for keratoconus treatment using the FDA-approved epi-off protocol, directly converting previously self-pay procedure volumes into insured patient flows and expanding the addressable market from a narrow refractive surgery niche into mainstream ophthalmology practice.

The FDA's Breakthrough Device Designation programme, administered by CDRH under the 21st Century Cures Act of 2016, is a second critical policy mechanism. Epi-on cross-linking platforms seeking this designation benefit from accelerated review timelines and more frequent FDA interaction, reducing regulatory uncertainty for developers. Additionally, the CMS Hospital Outpatient Prospective Payment System (OPPS) APC classification for corneal cross-linking procedures directly determines facility reimbursement rates at ambulatory surgery centres, with the 2024 OPPS final rule maintaining favourable payment status. These two mechanisms together determine both the speed of new platform entry and the economic viability of each additional procedure performed at outpatient facilities nationwide.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier is the FDA's Premarket Approval (PMA) pathway requirement for new corneal cross-linking devices. Unlike lower-risk devices cleared through 510(k), cross-linking systems require full PMA submissions to CDRH's Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices (OOAREDD). PMA approval requires multi-site Investigational Device Exemption (IDE) clinical trials, which for ophthalmic devices typically cost USD 15–25 million and span 36–60 months. This creates an insurmountable barrier for smaller developers and has effectively preserved Glaukos's first-mover advantage since 2016. Any manufacturer pursuing epi-on approval must generate a separate PMA supplement with independent clinical endpoint data, not merely comparative bioequivalence arguments.

A secondary barrier is riboflavin drug-device combination product regulation. Because cross-linking systems use riboflavin ophthalmic solutions as an integral drug component, the FDA's Office of Combination Products coordinates review between CDRH and the Center for Drug Evaluation and Research (CDER). This dual-centre review adds 3–6 months to standard approval timelines and requires separate drug Current Good Manufacturing Practice (cGMP) compliance documentation. Compounding pharmacies that have historically supplied off-label riboflavin formulations face increasing FDA enforcement pressure following warning letters issued in 2022, which has reduced access to non-approved alternatives and concentrated procedure volume further around the single FDA-approved commercial drug-device combination.

Policy-Created Opportunities in U.S. Corneal Cross-Linking

The FDA's Real-World Evidence (RWE) programme, formalised under the 21st Century Cures Act and the FDA's 2021 RWE Framework, creates a direct opportunity for manufacturers to support PMA supplement submissions with registry-based post-market data rather than exclusively de novo prospective trials. Glaukos's CXLR registry, which has enrolled over 10,000 U.S. patients, positions the company to leverage RWE pathways for expanded labelling — including paediatric keratoconus indications and post-LASIK ectasia treatment — without conducting entirely new IDE trials. Paediatric expansion is particularly significant given the National Eye Institute's recognition of keratoconus as a priority condition in its 2021–2025 Strategic Plan, which directs NIH funding toward juvenile corneal disease research and supports investigator-initiated trial infrastructure.

The Veterans Health Administration (VHA) and the Department of Defense's Military Health System (MHS) represent an underserved, policy-determined procurement opportunity. VA Directive 1121, which governs prosthetics and sensory aids procurement, covers corneal cross-linking as a covered surgical benefit for eligible veterans with service-connected keratoconus. The VHA's National Acquisition Center maintains formulary negotiations with device suppliers, and the DoD's Defence Health Agency is currently reviewing inclusion of cross-linking in its TRICARE surgical benefits for active-duty personnel. Securing VHA and DHA formulary positioning before 2027 represents a contracted volume opportunity estimated at 8,000–12,000 procedures annually that bypasses commercial payer negotiation entirely.

Market at a Glance

Leading Market Participants

• Glaukos Corporation
• Avedro (subsidiary of Glaukos)
• Bausch + Lomb
• Sight Sciences
• EMAGine AG
• Thea Pharma
• Oculus Surgical
• PhotoMedex
• Nidek Co., Ltd.
• Carl Zeiss Meditec AG

Regulatory and Policy Environment

The foundational regulatory instrument governing this market is the FDA's Premarket Approval order P120023, granted to Avedro in April 2016 for the KXL System in combination with Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5'-phosphate ophthalmic solution) for the treatment of progressive keratoconus and post-refractive surgery ectasia. This PMA order, administered by CDRH's OOAREDD division, specifies accelerated epi-off protocol parameters — including a minimum UV-A irradiance of 3 mW/cm² and a minimum treatment time of 30 minutes — as the legally mandated clinical standard. Deviations from these parameters outside a clinical trial constitute misbranding under the Federal Food, Drug, and Cosmetic Act. Compared to the European CE-mark environment, where multiple epi-on and Dresden-protocol devices operate under MDR 2017/745 without procedural parameter restrictions, the U.S. framework is significantly more constrictive, limiting procedural variation and slowing technology adoption.

Upcoming regulatory changes of direct market consequence include the FDA's planned finalisation of updated guidance on Predetermined Change Control Plans (PCCPs) for device software and energy delivery systems, expected in 2025, which will allow manufacturers to pre-specify future UV-A delivery algorithm modifications without full PMA supplements. Additionally, CMS is conducting a five-year review of CPT 92145 relative value units as part of its standard RUC (Relative Value Scale Update Committee) cycle, with revised physician payment rates expected in the 2026 Physician Fee Schedule final rule. A downward RVU adjustment — which the RUC has applied to multiple mature ophthalmic procedure codes in recent cycles — would reduce per-procedure physician reimbursement and disproportionately affect low-volume practices considering equipment investment, potentially consolidating procedure volume further into high-throughput specialised centres.

Long-Term Policy Outlook for U.S. Corneal Cross-Linking

By 2032, the most consequential policy shift anticipated in this market is FDA approval of at least one epi-on corneal cross-linking platform, which will require a separate PMA with independent clinical trial data demonstrating non-inferiority to the approved epi-off standard on the primary endpoint of maximum keratometry stabilisation. If approved, epi-on technology will trigger a new CPT coding application to the AMA Editorial Panel, as the procedural differentiation from current CPT 92145 is clinically and technically substantive. A new Category III or Category I code for epi-on procedures will reset payer coverage timelines, creating a 2–4 year coverage gap during which epi-on procedures remain primarily self-pay — a pattern that exactly mirrored the post-2016 trajectory of the original epi-off approval.

Federal health equity policy will increasingly shape geographic market expansion through 2032. The HHS Office of Minority Health has identified keratoconus as disproportionately prevalent in Hispanic and African American populations, and ongoing NIH-funded epidemiological work through the National Eye Institute is expected to generate data by 2027 supporting targeted screening programme recommendations. If NIH and the U.S. Preventive Services Task Force formalise a screening recommendation, CMS coverage for diagnostic topography preceding cross-linking will expand, creating an upstream demand catalyst. Simultaneously, the ongoing consolidation of ophthalmology practices under private equity — currently operating under scrutiny from the Federal Trade Commission's 2024 healthcare consolidation enforcement priorities — will face structural constraints that may preserve independent practice procedure volumes longer than market consensus currently expects.